Burning Rock Publishes 2025 Annual Report on Form 20-F

Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F on April 28, 2026, for the year ended December 31, 2025.

Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F on April 28, 2026, for the year ended December 31, 2025. The filing is available on the SEC website and the company investor site.

The Form 20-F includes the audited consolidated financial statements. Shareholders and ADS holders may request a free hard copy by mail or email to the company.

Argus Apr 28 session

-12.64% close to close Open Argus

Details

News Market Reaction – BNR

In the Apr 28 session, BNR declined 12.64%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -12.6% in the session following this news. A negative reaction despite a routine 2...

Analysis

The stock dropped -12.6% in the session following this news. A negative reaction despite a routine 20‑F filing fits a pattern where Burning Rock’s shares often declined after various announcements, including earnings and AGM outcomes, regardless of operational improvements. The filing formalizes 2025 results already highlighted in earlier reports, so selling may reflect positioning rather than new financial surprises. Prior episodes show that even insider purchases sometimes coincided with short‑term weakness, underscoring the stock’s sensitivity around disclosure dates.

Historical Context

5 past events · Latest: Apr 02

5 events

1. Apr 02

   Insider share purchase

   24h Move

   -0.6%

   Founder disclosed additional ADS purchases totaling 31,487 ADSs in open market.

2. Mar 12

   Earnings results

   24h Move

   -2.6%

   Reported 2025 revenue growth, higher gross margin, and lower operating expenses.

3. Jan 05

   Insider share purchase

   24h Move

   +24.4%

   Founder announced US$811,721.28 of ADS purchases from the open market.

4. Dec 22

   AGM results

   24h Move

   -6.9%

   All 2025 AGM resolutions passed, including auditor ratification and director re‑elections.

5. Dec 01

   AGM announcement

   24h Move

   -12.0%

   Announced date, agenda and record date for 2025 Annual General Meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, u.s. securities and exchange commission, next generation sequencing, precision oncology, +1 more

5 terms

form 20-f regulatory

"it filed its Annual Report on Form 20-F for the year ended December 31, 2025"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

u.s. securities and exchange commission regulatory

"with the U.S. Securities and Exchange Commission (“SEC”)."

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

next generation sequencing medical

"focused on the application of next generation sequencing technology in the field"

A collection of advanced laboratory methods that read and map large amounts of DNA or RNA quickly and at lower cost than older techniques; think of it as scanning thousands of pages of a book at once instead of reading one page at a time. Investors care because it accelerates drug development, enables precise diagnostics and personalized treatments, and can create recurring revenue from tests, instruments, and data services as adoption expands.

precision oncology medical

"technology in the field of precision oncology, announces that on April 28, 2026"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

ads financial

"to its shareholders and ADS holders upon request."

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company’s website at http://ir.brbiotech.com. The Company will provide a hard copy of the Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Burning Rock Biotech Limited, No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, or via email at IR@brbiotech.com.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: http://ir.brbiotech.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

FAQ

What did Burning Rock (BNR) file on April 28, 2026?

Burning Rock filed its Annual Report on Form 20-F for the year ended December 31, 2025. According to the company, the Form 20-F includes audited consolidated financial statements and is available on the SEC and company investor websites.

Where can investors view Burning Rock's 2025 Form 20-F for BNR?

Investors can view the Form 20-F on the SEC website and the company's investor site. According to the company, the filing is posted at www.sec.gov and at http://ir.brbiotech.com for direct access.

Does the Burning Rock 20-F include audited financial statements for 2025?

Yes. The Form 20-F contains audited consolidated financial statements for the year ended December 31, 2025. According to the company, shareholders and ADS holders may request a free hard copy of those audited statements.

How can shareholders request a hard copy of Burning Rock's 2025 Form 20-F?

Shareholders can request a free hard copy by mail or email to the company. According to the company, requests should be sent to its Guangzhou address or to IR@brbiotech.com for fulfillment.

What does the BNR Form 20-F filing mean for investors?

The filing provides the company's audited annual disclosure required for U.S.-listed foreign issuers. According to the company, the Form 20-F supplies investors with consolidated financials and other statutory disclosures for review.